Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01528137 · ClinicalTrials.gov registry record · Phase 1
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01528137: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT01528137 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01528137, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase I trial studies how well talactoferrin works in treating patients with relapsed or refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer. Biological therapies, such as talactoferrin, may stimulate the immune system in different ways and stop tumor cells from growing
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL talactoferrin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01528137
The ClinicalTrials.gov registry entry for NCT01528137 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01528137 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01528137 about?
NCT01528137 is a clinical study titled "Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer". This phase I trial studies how well talactoferrin works in treating patients with relapsed or refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer. Biological therapies, such as talactoferrin, may stimulate the immune system in different ways and stop tumor cells from ...
What is the current status of trial NCT01528137?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2012-05. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01528137?
The interventions under investigation include: laboratory biomarker analysis (OTHER), talactoferrin (BIOLOGICAL).
Who is sponsoring clinical trial NCT01528137?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.